Lyell Immunopharma Inc. has announced positive new clinical data from a multi-center Phase 1/2 trial of its LYL314 treatment for aggressive large B-cell lymphoma. The trial demonstrated an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting. Among those achieving a complete response, 71% remained in complete response for at least six months. The treatment, LYL314, is an autologous dual-targeting CD19/CD20 chimeric antigen receptor $(CAR)$ T-cell product candidate with Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, aimed at relapsed and/or refractory large B-cell lymphoma. A pivotal single-arm PiNACLE trial is currently underway in CAR T-naïve patients. The clinical data will be presented on June 18, 2025, at the International Conference on Malignant Lymphoma in Lugano, Switzerland.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。